(Q37641646)

21 August 2017

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma (English)

1 reference

21 August 2017

0 references

1 reference

ChEBI release 2020-05-28

ChEBI ID

75998

author

Katherine L Nathanson

28

1 reference

21 August 2017

Melissa Wilson

9

0 references

Meenhard Herlyn

27

object named as

Meenhard Herlyn

1 reference

21 August 2017

10

Adina Vultur

1 reference

21 August 2017

3

Clemens Krepler

1 reference

21 August 2017

22

Giorgos C Karakousis

1 reference

21 August 2017

15

Katrin Sproesser

1 reference

21 August 2017

8

Rolf K Swoboda

1 reference

21 August 2017

5

Minu Samanta

1 reference

21 August 2017

Jessie Villanueva

1

1 reference

21 August 2017

Jeffrey R Infante

2

1 reference

21 August 2017

Patricia Reyes-Uribe

4

1 reference

21 August 2017

Hsin-Yi Chen

6

1 reference

21 August 2017

Bin Li

7

1 reference

21 August 2017

Mizuho Fukunaba-Kalabis

11

1 reference

21 August 2017

Bradley Wubbenhorst

12

1 reference

21 August 2017

Thomas Y Chen

13

1 reference

21 August 2017

Qin Liu

14

1 reference

21 August 2017

Douglas J DeMarini

16

1 reference

21 August 2017

Tona M Gilmer

17

1 reference

21 August 2017

Anne-Marie Martin

18

1 reference

21 August 2017

Ronen Marmorstein

19

1 reference

21 August 2017

David C Schultz

20

1 reference

21 August 2017

David W Speicher

21

1 reference

21 August 2017

Wei Xu

23

1 reference

21 August 2017

Ravi K Amaravadi

24

1 reference

21 August 2017

Xiaowei Xu

25

1 reference

21 August 2017

Lynn M Schuchter

26

1 reference

21 August 2017

19 September 2013

1 reference

21 August 2017

1 reference

21 August 2017

4

1 reference

21 August 2017

6

1 reference

21 August 2017

1090-1099

1 reference

describes a project that uses

21 August 2017

0 references

0 references

0 references

0 references

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

MEK1 mutations confer resistance to MEK and B-RAF inhibition

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

BRAF mutation predicts sensitivity to MEK inhibition

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

ERK inhibition overcomes acquired resistance to MEK inhibitors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

BRAF targeted therapy changes the treatment paradigm in melanoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3956616

10.1016/J.CELREP.2013.08.023

25 June 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

21 August 2017

PubMed publication ID

24055054

1 reference